HGF-MET cascade, a key target for inhibiting cancer metastasis: The impact of NK4 discovery on cancer biology and therapeutics

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 888-919

  Mizuno, Shinya ^a   Nakamura, Toshikazu ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cancer invasion and metastasis; HGF; MET; NK4; Oncogenesis; Perlecan

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; DECORIN; HEPATOCYTE GROWTH FACTOR ALPHA CHAIN N TERMINAL HAIRPAIN DOMAIN AND 4 KRINGLE DOMAIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; HGF PROTEIN, HUMAN; PROTEIN BINDING;

ANOIKIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL HOMING; CELL MOTION; CELL REGENERATION; DRUG PROTEIN BINDING; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HYPOXIA; IMMUNOLOGICAL TOLERANCE; METASTASIS INHIBITION; NONHUMAN; ORGANOGENESIS; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; METASTASIS; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; VASCULARIZATION;

MUS; RATTUS;

ANGIOGENESIS INHIBITORS; ANIMALS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; RATS; SIGNAL TRANSDUCTION;

EID: 84872174511     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010888     Document Type: Review

References (133)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Nakamura, T.; Nawa, K.; Ichihara, A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 1984, 122, 1450-1459.
3. Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342, 440-443.
4. Nakamura, T. Structure and function of hepatocyte growth factor. Prog. Growth Factor Res. 1991, 3, 67-85.
5. Boros, P.; Miller, C.M. Hepatocyte growth factor: A multifunctional cytokine. Lancet 1995, 345, 293-295.
6. Rosário, M.; Birchmeier, W. How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 2003, 13, 328-335.
7. Gherardi, E.; Sandin, S.; Petoukhov, M.V.; Finch, J.; Youles, M.E.; Ofverstedt, L.G.; Miguel, R.N.; Blundell, T.L.; Vande Woude, G.F.; Skoglund, U.; et al. Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc. Natl. Acad. Sci. 2006, 103, 4046-4051.
8. Nakamura, T.; Mizuno, S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn. Acad. Ser. B 2010, 86, 588-610.
9. Bottaro, D.P.; Rubin, J.S.; Faletto, D.L.; Chan, A.M., Kmiecik, T.E., Vande Woude, G.F.; Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802-804.
10. Higuchi, O.; Mizuno, K.; Vande Woude, G.F.; Nakamura, T. Expression of c-met proto-oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor. FEBS Lett. 1992, 301, 282-286.
11. Matsumoto, K.; Matsumoto, K.; Nakamura, T.; Kramer, R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 1994, 269, 31807-31813.
12. Nakamura, T.; Matsumoto, K.; Kiritoshi, A.; Tano, Y.; Nakamura, T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res. 1997, 57, 3305-3313.
13. Matsumoto, K.; Date, K.; Ohmichi, H.; Nakamura, T. Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions. Cancer Chemother. Pharmacol. 1996, 38, S42-S47.
14. Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M.; et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 1997, 16, 68-73.
15. Date, K.; Matsumoto, K.; Shimura, H.; Tanaka, M.; Nakamura, T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 1997, 420, 1-6.
16. Date, K.; Matsumoto, K.; Kuba, K.; Shimura, H.; Tanaka, M.; Nakamura, T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998, 17, 3045-3054.
17. Dean, M.; Park, M.; Le Beau, M.M.; Robins, T.S.; Diaz, M.O.; Rowley, J.D.; Blair, D.G.; Vande Woude, G.F. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985, 318, 385-388.
18. Nakamura, T.; Nawa, K.; Ichihara, A.; Kaise, N.; Nishino, T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 1987, 224, 311-316.
19. Stoker, M.; Gherardi, E.; Perryman, M.; Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327, 239-242.
20. Konishi, T.; Takehara, T.; Tsuji, T.; Ohsato, K.; Matsumoto, K.; Nakamura, T. Scatter factor from human embryonic lung fibroblasts is probably identical to hepatocyte growth factor. Biochem. Biophys. Res. Commun. 1991, 180, 765-773.
21. Weidner, K.M.; Arakaki, N.; Hartmann, G.; Vandekerckhove, J.; Weingart, S.; Rieder, H.; Fonatsch, C.; Tsubouchi, H.; Hishida, T.; Daikuhara, Y.; et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. 1991, 88, 7001-7005.
22. Ohmichi, H.; Koshimizu, U.; Matsumoto, K.; Nakamura, T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 1998, 125, 1315-1324.
23. Ishiki, Y.; Ohnishi, H.; Muto, Y.; Matsumoto, K.; Nakamura, T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 1992, 16, 1227-1235.
24. Nakamura, T.; Mizuno, S.; Matsumoto, K.; Sawa, Y.; Matsuda, H.; Nakamura, T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106, 1511-1519.
25. Mizuno, S.; Ohnishi, H.; Nakamura, T. Hepatocyte growth factor (HGF), an endogenous pulmotrophic regulator, for the rescue of acute and chronic lung diseases. Curr. Signal Transduct. Ther. 2011, 6, 210-220.
26. Kanda, H.; Tajima, H.; Lee, G.H.; Nomura, K.; Ohtake, K.; Matsumoto, K.; Nakamura, T.; Kitagawa, T. Hepatocyte growth factor transforms immortalized mouse liver epithelial cells. Oncogene 1993, 8, 3047-3053.
27. Takayama, H.; LaRochelle, W.J.; Sharp, R.; Otsuka, T.; Kriebel, P.; Anver, M.; Aaronson, S.A.; Merlino, G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. 1997, 94, 701-706.
28. Stabile, L.P.; Lyker, J.S.; Land, S.R.; Dacic, S.; Zamboni, B.A.; Siegfried, J.M. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006, 27, 1547-1555.
29. Di Renzo, M.F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A.D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinoma. Oncogene 2000, 19, 1547-1555.
30. Ma, P.C.; Kijima, T.; Maulik, G.; Fox, E.A.; Sattler, M.; Griffin, J.D.; Johnson, B.E.; Salgia R. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003, 63, 6272-6281.
31. Krishnaswamy, S.; Kanteti, R.; Duke-Cohan, J.S.; Loganathan, S.; Liu, W.; Ma, P.C.; Sattler, M.; Singleton, P.A.; Ramnath, N.; Innocenti, F.; et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin. Cancer Res. 2009, 15, 5714-5723.
32. Giordano, S.; Maffe, A.; Williams, T.A.; Artigiani, S.; Gual, P.; Bardelli, A.; Basilico, C.; Michieli, P.; Comoglio, P.M. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J. 2000, 14, 399-406.
33. Danilkovitch-Miagkova, A.; Miagkov, A.; Skeel, A.; Nakaigawa, N.; Zbar, B.; Leonard, E.J. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol. Cell Biol. 2001, 21, 5857-5868.
34. Nakaigawa, N.; Weirich, G.; Schmidt, L.; Zbar, B. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene 2000, 19, 2996-3002.
35. Lin, H.C.; Lai, P.Y.; Lin, Y.P.; Huang, J.Y.; Yang, B.C. Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts. J. Biol. Chem. 2012, 287, 20664-20673.
36. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
37. Karamouzis, M.V.; Konstantinopoulos, P.A.; Papavassiliou, A.G. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol. 2009, 10, 709-717.
38. Shattuck, D.L.; Miller, J.K.; Carraway, K.L.; Sweeney, C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68, 1471-1477.
39. Guo, A.; Villén, J.; Kornhauser, J.; Lee, K.A.; Stokes, M.P.; Rikova, K.; Possemato, A.; Nardone, J.; Innocenti, G.; Wetzel, R.; et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. 2008, 105, 692-697.
40. Tanizaki, J.; Okamoto, I.; Sakai, K.; Nakagawa, K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer 2011, 105, 807-813.
41. Miura, H.; Nishimura, K.; Tsujimura, A.; Matsumiya, K.; Matsumoto, K.; Nakamura, T.; Okuyama, A. Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells. Urology 2001, 58, 1064-1069.
42. Kimura, T.; Sakisaka, T.; Baba, T.; Yamada, T.; Takai, Y. Involvement of the Ras-Ras-activated Rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis of E-cadherin. J. Biol. Chem. 2006, 281, 10598-10609.
43. Hiscox, S.; Jiang, W.G. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: Involvement of beta-catenin. Anticancer Res. 1999, 19, 509-517.
44. Royal, I.; Lamarche-Vane, N.; Lamorte, L.; Kaibuchi, K.; Park, M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell 2000, 11, 1709-1725.
45. Parr, C.; Davies, G.; Nakamura, T.; Matsumoto, K.; Mason, M.D.; Jiang, W.G. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem. Biophys. Res. Commun. 2001, 285, 1330-1337.
46. Li, H.; Shimura, H.; Aoki, Y.; Date, K.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin. Exp. Metastasis 1998, 16, 74-82.
47. Nagakawa, O.; Murakami, K.; Yamaura, T.; Fujiuchi, Y.; Murata, J.; Fuse, H.; Saiki, I. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 2000, 155, 173-179.
48. Jiang, Y.; Xu, W.; Lu, J.; He, F.; Yang, X. Invasiveness of hepatocellular carcinoma cell lines: Contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem. Biophys. Res. Commun. 2001, 286, 1123-1130.
49. Zeng, Q.; Chen, S.; You, Z.; Yang, F.; Carey, T.E.; Saims, D.; Wang, C.Y. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J. Biol. Chem. 2002, 277, 25203-25208.
50. Franco, M.; Muratori, C.; Corso, S.; Tenaglia, E.; Bertotti, A.; Capparuccia, L.; Trusolino, L.; Comoglio, P.M.; Tamagnone, L. The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J. Biol. Chem. 2010, 285, 38756-38764.
51. Huang, S.; Ouyang, N.; Lin, L.; Chen, L.; Wu, W.; Su, F.; Yao, Y.; Yao, H. HGF-induced PKC. activation increases functional CXCR4 expression in human breast cancer cells. PLoS One 2012, 7, e29124.
52. Tu, H.; Zhou, Z.; Liang, Q.; Li, Z.; Li, D.; Qing, J.; Wang, H.; Zhang, L. CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie 2009, 32, 331-336.
53. Bussolino, F.; Di Renzo, M.F.; Ziche, M.; Bocchietto, E.; Olivero, M.; Naldini, L.; Gaudino, G.; Tamagnone, L.; Coffer, A.; Comoglio, P.M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 1992, 119, 629-641.
54. Kuba, K.; Matsumoto, K.; Date, K.; Shimura, H.; Tanaka, M.; Nakamura, T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000, 60, 6737-6743.
55. Kubota, T.; Taiyoh, H.; Matsumura, A.; Murayama, Y.; Ichikawa, D.; Okamoto, K.; Fujiwara, H.; Ikoma, H.; Nakanishi, M.; Kikuchi, S.; et al. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin. Exp. Metastasis 2009, 26, 447-456.
56. Jiang, W.G.; Martin, T.A.; Matsumoto, K.; Nakamura, T.; Mansel, R.E. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J. Cell Physiol. 1999, 181, 319-329.
57. Rutella, S.; Danese, S.; Leone, G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108, 1435-1440.
58. Michieli, P.; Basilico, C.; Pennacchietti, S.; Maffè, A.; Tamagnone, L.; Giordano, S.; Bardelli, A.; Comoglio, P.M. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999, 18, 5221-5231.
59. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3, 347-361.
60. Kitajima, Y.; Ide, T.; Ohtsuka, T.; Miyazaki, K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008, 99, 1341-1347.
61. Nakamura, Y.; Morishita, R.; Higaki, J.; Kida, I.; Aoki, M.; Moriguchi, A.; Yamada, K.; Hayashi, S.; Yo, Y.; Nakano, H.; et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: Additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J. Hypertens. 1996, 14, 1067-1072.
62. Laterra, J.; Nam, M.; Rosen, E.; Rao, J.S.; Lamszus, K.; Goldberg, I.D.; Johnston, P. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab. Invest. 1997, 76, 565-577.
63. Kubota, T.; Taiyoh, H.; Matsumura, A.; Murayama, Y.; Ichikawa, D.; Okamoto, K.; Fujiwara, H.; Ikoma, H.; Nakanishi, M.; Kikuchi, S.; et al. Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation. Int. J. Cancer 2009, 125, 2879-2886.
64. Matsumoto-Taniura, N.; Matsumoto, K.; Nakamura, T. Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts. Br. J. Cancer 1999, 81, 194-202.
65. Hasina, R.; Matsumoto, K.; Matsumoto-Taniura, N.; Kato, I.; Sakuda, M.; Nakamura, T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br. J. Cancer 1999, 80, 1708-1717.
66. Matsumoto, K.; Nakamura, T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003, 94, 321-327.
67. Wislez, M.; Rabbe, N.; Marchal, J.; Milleron, B.; Crestani, B.; Mayaud, C.; Antoine, M.; Soler, P.; Cadranel, J. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res. 2003, 63, 1405-1412.
68. Osada, S.; Kanematsu, M.; Imai, H.; Goshima, S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008, 55, 544-549.
69. Beppu, K.; Uchiyama, A.; Morisaki, T.; Matsumoto, K.; Nakamura, T.; Tanaka, M.; Katano, M. Hepatocyte growth factor production by peripheral blood mononuclear cells of recurrent cancer patients. Anticancer Res. 2001, 21, 2195-2200.
70. Matsumoto, K.; Kataoka, H.; Date, K.; Nakamura, T. Cooperative interaction between alpha-and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J. Biol. Chem. 1998, 273, 22913-22920.
71. Otsuka, T.; Jakubczak, J.; Vieira, W.; Bottaro, D.P.; Breckenridge, D.; Larochelle, W.J.; Merlino, G. Disassociation of met-mediated biological responses in vivo: The natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell Biol. 2000, 20, 2055-2065.
72. Jiang, W.G.; Hiscox, S.E.; Parr, C.; Martin, T.A.; Matsumoto, K.; Nakamura, T.; Mansel, R.E. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin. Cancer Res. 1999, 5, 3695-3703.
73. Sakai, K.; Nakamura, T.; Matsumoto, K.; Nakamura, T. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J. Biol. Chem. 2009, 284, 22491-22499.
74. Ohnishi, H.; Oka, K.; Mizuno, S.; Nakamura, T. Identification of mannose receptor as receptor for hepatocyte growth factor beta-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis. J. Biol. Chem. 2012, 287, 13371-13381.
75. Buchstein, N.; Hoffmann, D.; Smola, H.; Lang, S.; Paulsson, M.; Niemann, C.; Krieg, T.; Eming, S.A. Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am. J. Pathol. 2009, 174, 2116-21128.
76. Wright, T.G.; Singh, V.K.; Li, J.J.; Foley, J.H.; Miller, F.; Jia, Z.; Elliott, B.E. Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model. Int. J. Cancer. 2009, 125, 1004-1015.
77. Dai, Y.; Siemann, D.W. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 2012, 12, e198.
78. Yancopoulos, G.D.; Klagsbrun, M.; Folkman, J. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border. Cell 1998, 93, 661-664.
79. Tomioka, D.; Maehara, N.; Kuba, K.; Mizumoto, K.; Tanaka, M.; Matsumoto, K.; Nakamura, T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001, 61, 7518-7524.
80. Saimura, M.; Nagai, E.; Mizumoto, K.; Maehara, N.; Minamishima, Y.A.; Katano, M.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin. Cancer Res. 2002, 8, 3243-3249.
81. Kishi, Y.; Kuba, K.; Nakamura, T.; Wen, J.; Suzuki, Y.; Mizuno, S.; Nukiwa, T.; Matsumoto, K.; Nakamura, T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 2009, 100, 1351-1358.
82. Fan, S.; Ma, Y.X.; Wang, J.A.; Yuan, R.Q.; Meng, Q.; Cao, Y.; Laterra, J.J.; Goldberg, I.D.; Rosen, E.M. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000, 19, 2212-2223.
83. Bowers, D.C.; Fan, S.; Walter, K.A.; Abounader, R.; Williams, J.A.; Rosen, EM.; Laterra, J. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKT-dependent pathways. Cancer Res. 2000, 60, 4277-4283.
84. Matsumoto, G.; Omi, Y.; Lee, U.; Kubota, E.; Tabata, Y. NK4 gene therapy combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma. Anticancer Res. 2011, 31, 105-111.
85. Yano, S.; Wang, W.; Li, Q.; Matsumoto, K.; Sakurama, H.; Nakamura, T.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Nishioka, Y.; et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68, 9479-9487.
86. Ohuchida, K.; Mizumoto, K.; Murakami, M.; Qian, L.W.; Sato, N.; Nagai, E.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 2004, 64, 3215-3222.
87. Sheng-Hua, C.; Yan-Bin, M.; Zhi-An, Z.; Hong, Z.; Dong-Fu, F.; Zhi-Qiang, L.; Xian-Hou, Y. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg. Neurol. 2007, 68, 610-613.
88. Hu, S.Y.; Duan, H.F.; Li, Q.F.; Yang, Y.F.; Chen, J.L.; Wang, L.S.; Wang, H. Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage. Acta Pharmacol. Sin. 2009, 30, 1415-1420.
89. Lynn, K.D.; Brekken, R.A. Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer? Cancer Discov. 2012, 2, 211-213.
90. Li, Y.; Li, A.; Glas, M.; Lal, B.; Ying, M.; Sang, Y.; Xia, S.; Trageser, D.; Guerrero-Cázares, H.; Eberhart, C.G.; et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. 2011, 108, 9951-9956.
91. + cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int. J. Cancer 2011, 129, 2337-2348.
92. Matsumoto, K.; Nakamura, T. Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem. Biophys. Res. Commun. 2005, 333, 316-327.
93. Ueda, K.; Iwahashi, M.; Matsuura, I.; Nakamori, M.; Nakamura, M.; Ojima, T.; Naka, T.; Ishida, K.; Matsumoto, K.; Nakamura, T.; et al. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur. J. Cancer 2004, 40, 2135-2142.
94. Son, G.; Hirano, T.; Seki, E.; Iimuro, Y.; Nukiwa, T.; Matsumoto, K.; Nakamura, T.; Fujimoto, J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J. Hepatol. 2006, 45, 688-695.
95. Wen, J.; Matsumoto, K.; Taniura, N.; Tomioka, D.; Nakamura, T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther. 2004, 11, 419-430.
96. Maemondo, M.; Narumi, K.; Saijo, Y.; Usui, K.; Tahara, M.; Tazawa, R.; Hagiwara, K.; Matsumoto, K.; Nakamura, T.; Nukiwa, T. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol. Therapy 2002, 5, 177-185.
97. Suzuki, Y.; Sakai, K.; Ueki, J.; Xu, Q.; Nakamura, T.; Shimada, H.; Nakamura, T.; Matsumoto, K. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int. J. Cancer 2010, 127, 1948-1957.
98. Davies, G.; Mason, M.D.; Martin, T.A.; Parr, C.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Jiang, W.G. The HGF/SF antagonist NK4 reverses fibroblast-and HGF-induced prostate tumor growth and angiogenesis in vivo. Int. J. Cancer 2003, 106, 348-354.
99. Saga, Y.; Mizukami, H.; Suzuki, M.; Urabe, M.; Kume, A.; Nakamura, T.; Sato, I.; Ozawa, K. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther. 2001, 8, 1450-1455.
100. Kikuchi, T.; Maemondo, M.; Narumi, K.; Matsumoto, K.; Nakamura, T.; Nukiwa, T. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood 2002, 100, 3950-3959.
101. Du, W.; Hattori, Y.; Yamada, T.; Matsumoto, K.; Nakamura, T.; Sagawa, M.; Otsuki, T.; Niikura, T.; Nukiwa, T.; Ikeda, Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: Molecular targeting of angiogenic growth factor. Blood 2007, 109, 3042-3049.
102. Brockmann, M.A.; Papadimitriou, A.; Brandt, M.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res. 2003, 9, 4578-4585.
103. Martin, T.A.; Parr, C.; Davies, G.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Mansel, R.E.; Jiang, W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003, 24, 1317-1323.
104. Abounader, R.; Ranganathan, S.; Lal, B.; Fielding, K.; Book, A.; Dietz, H.; Burger, P.; Laterra, J. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 1999, 91, 1548-1556.
105. Cao, B.; Su, Y.; Oskarsson, M.; Zhao, P.; Kort, E.J.; Fisher, R.J.; Wang, L.M.; Vande Woude, G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. 2001, 98, 7443-7448.
106. Mazzone, M.; Basilico, C.; Cavassa, S.; Pennacchietti, S.; Risio, M.; Naldini, L.; Comoglio, P.M.; Michieli, P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 2004, 114, 1418-1432.
107. Kirchhofer, D.; Lipari, M.T.; Santell, L.; Billeci, K.L.; Maun, H.R.; Sandoval, W.N.; Moran, P.; Ridgway, J.; Eigenbrot, C.; Lazarus, R.A. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc. Natl. Acad. Sci. 2007, 104, 5306-5311.
108. Jones, D.S.; Tsai, P.C.; Cochran, J.R. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc. Natl. Acad. Sci. 2011, 108, 13035-13040.
109. Otsuka, T.; Takagi, H.; Horiguchi, N.; Toyoda, M.; Sato, K.; Takayama, H.; Mori, M.; CCl4-induced acute liver injury in mice is inhibited by hepatocyte growth factor overexpression but stimulated by NK2 overexpression. FEBS Lett. 2002, 532, 391-395.
110. Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.; Chen, Q.; Ho, S.Y.; Li, L.; Kaufman, S.; et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006, 66, 1721-1729.
111. Martens, T.; Schmidt, N.O.; Eckerich, C.; Fillbrandt, R.; Merchant, M.; Schwall, R.; Westphal, M.; Lamszus, K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 2006, 12, 6144-6152.
112. Petrelli, A.; Circosta, P.; Granziero, L.; Mazzone, M.; Pisacane, A.; Fenoglio, S.; Comoglio, P.M.; Giordano, S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. 2006, 103, 5090-5095.
113. Greenall, S.A.; Gherardi, E.; Liu, Z.; Donoghue, J.F.; Vitali, A.A.; Li, Q.; Murphy, R.; Iamele, L.; Scott, A.M.; Johns, T.G. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One 2012, 7, e34658.
114. Bardelli, A.; Longati, P.; Gramaglia, D.; Stella, M.C.; Comoglio, P.M. Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 1997, 15, 3103-3111.
115. Puri, N.; Khramtsov, A.; Ahmed, S.; Nallasura, V.; Hetzel, J.T.; Jagadeeswaran, R.; Karczmar, G.; Salgia, R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007, 67, 3529-3534.
116. Pan, B.S.; Chan, G.K.; Chenard, M.; Chi, A.; Davis, L.J.; Deshmukh, S.V.; Gibbs, J.B.; Gil, S.; Hang, G.; Hatch, H.; et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010, 70, 1524-1533.
117. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 553-572.
118. Buraschi, S.; Pal, N.; Tyler-Rubinstein, N.; Owens, R.T.; Neill, T.; Iozzo, R.V. Decorin antagonizes Met receptor activity and down-regulates ß-catenin and Myc levels. J. Biol. Chem. 2010, 285, 42075-42085.
119. Yamamoto, B.J.; Elias, P.D.; Masino, J.A.; Hudson, B.D.; McCoy, A.T.; Anderson, Z.J.; Varnum, M.D.; Sardinia, M.F.; Wright, J.W.; Harding, J.W. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J. Pharmacol. Exp. Ther. 2010, 333, 161-173.
120. Kong-Beltran, M.; Stamos, J.; Wickramasinghe, D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004, 6, 75-84.
121. Zhao, P.; Grabinski, T.; Gao, C.; Skinner, R.S.; Giambernardi, T.; Su, Y.; Hudson, E.; Resau, J.; Gross, M.; Vande Woude, G.F.; et al. Identification of a met-binding peptide from a phage display library. Clin. Cancer Res. 2007, 13, 6049-6055.
122. Tuynman, J.B.; Vermeulen, L.; Boon, E.M.; Kemper, K.; Zwinderman, A.H.; Peppelenbosch, M.P.; Richel, D.J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68, 1213-1220.
123. Lee, W.J.; Chen, W.K.; Wang, C.J.; Lin, W.L.; Tseng, T.H. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol. 2008, 226, 178-191.
124. Koh, Y.W.; Choi, E.C.; Kang, S.U.; Hwang, H.S.; Lee, M.H.; Pyun, J.; Park, R.; Lee, Y.; Kim, C.H. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J. Nutr. Biochem. 2011, 22, 1074-1083.
125. Hung, C.M.; Kuo, D.H.; Chou, C.H.; Su, Y.C.; Ho, C.T.; Way, T.D. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J. Agric. Food Chem. 2011, 59, 9683-9690.
126. Ma, J.; DeFrances, M.C.; Zou, C.; Johnson, C.; Ferrell, R.; Zarnegar, R. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J. Clin. Invest. 2009, 119, 478-491.
127. Chen, J.T.; Lin, T.S.; Chow, K.C.; Huang, H.H.; Chiou, S.H.; Chiang, S.F.; Chen, H.C.; Chuang, T.L.; Lin, T.Y.; Chen, C.Y. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am. J. Respir. Cell Mol. Biol. 2006, 34, 264-273.
128. Kanehira, M.; Xin, H.; Hoshino, K.; Maemondo, M.; Mizuguchi, H.; Hayakawa, T.; Matsumoto, K.; Nakamura, T.; Nukiwa, T.; Saijo, Y. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2007, 14, 894-903.
129. Okasora, T.; Jo, J.I.; Tabata, Y. Augmented anti-tumor therapy through natural targetability of macrophages genetically engineered by NK4 plasmid DNA. Gene Ther. 2008, 15, 524-530.
130. Kushibiki, T.; Matsumoto, K.; Nakamura, T.; Tabata Y. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther. 2004, 11, 1205-1214.
131. Hay, R.V.; Cao, B.; Skinner, R.S.; Su, Y.; Zhao, P.; Gustafson, M.F.; Qian, C.N.; The, B.T.; Knudsen, B.S.; Resau, J.H.; et al. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin. Cancer Res. 2005, 11, 7064s-7069s.
132. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500-504.
133. Eder, J.P.; Vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207-2214.